Now trading at an ‘attractive price’, why CSL shares look set for a rebound

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.

Image source: Getty Images

CSL Ltd (ASX: CSL) shares are marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed on Friday trading for $234.34. In late morning trade on Monday, shares are changing hands for $238.05 apiece, up 1.6%.

For some context, the ASX 200 is up 0.2% at this same time.

Today’s outperformance will come as welcome news to stockholders. CSL shares are still down 19.0% since this time last year, trailing the 10.1% 12-month gains posted by the ASX 200.

But a growing number of fund managers expect the biotech giant to have a much stronger year ahead.

Why CSL shares could outpace the benchmark into 2026

“It’s rare to find quality businesses that are cheap. But occasionally, they are,” said…

Source link